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DNMT1 and UHRF1 inhibition in colon
cancer cells
Jung Seon Seo1, Young Ha Choi1, Ji Wook Moon2, Hyeon Soo Kim1 and Sun-Hwa Park1*
Abstract
Background: DNA hypermethylation is a key epigenetic mechanism for the silencing of many genes in cancer. Hinokitiol,
a tropolone-related natural compound, is known to induce apoptosis and cell cycle arrest and has anti-inflammatory and
anti-tumor activities. However, the relationship between hinokitiol and DNA methylation is not clear. The aim of our study
was to explore whether hinokitiol has an inhibitory ability on the DNA methylation in colon cancer cells.
Results: MTT data showed that hinokitiol had higher sensitivity in colon cancer cells, HCT-116 and SW480, than in normal
colon cells, CCD18Co. Hinokitiol reduced DNA methyltransferase 1 (DNMT1) and ubiquitin-like plant homeodomain and
RING finger domain 1 (UHRF1) expression in HCT-116 cells. In addition, the expression of ten-eleven translocation protein
1 (TET1), a known DNA demethylation initiator, was increased by hinokitiol treatment. ELISA and FACS data showed that
hinokitiol increased the 5-hydroxymethylcytosine (5hmC) level in the both colon cancer cells, but 5-methylcytosine (5mC)
level was not changed. Furthermore, hinokitiol significantly restored mRNA expression of O6-methylguanine DNA
methyltransferase (MGMT), carbohydrate sulfotransferase 10 (CHST10), and B-cell translocation gene 4 (BTG4) concomitant
with reduction of methylation status in HCT-116 cells.
Conclusions: These results indicate that hinokitiol may exert DNA demethylation by inhibiting the expression of DNMT1
and UHRF1 in colon cancer cells.
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Background
Epigenetic modifications are responsible for the initi-
ation and maintenance of gene silencing. Hypermethy-
lation of a CpG island in a promoter region is the
most well-established epigenetic alteration. Aberrant
promoter methylation causes transcriptional inactiva-
tion of many genes involved in tumor suppression, cell
cycle regulation, apoptosis, and DNA repair. Modified
DNA methylation is found in various types of cancer
during carcinogenesis [1, 2]. DNA methylation is
mediated by DNA methyltransferases (DNMTs), which
catalyzes the transfer of methyl groups to C5 of
cytosine from S-adenosyl methionine [3]. DNMT1
maintains DNA methylation and possesses de novo
methyltransferase activity during DNA replication,
and DNMT3A and DNMT3B play an important role
as de novo methyltransferases. DNMTs interact with
transcriptional repression factors and histone deacety-
lases (HDACs) and thus directly causes transcription
inactivation [4]. DNMT1 is recruited by replication
foci via its interaction with the ubiquitin-like plant
homeodomain and RING finger domain 1 (UHRF1). It
was well known that UHRF1 is involved in de novomethy-
lation of DNMT3A and DNMT3B and plays a pivotal role
in carcinogenesis through gene silencing mechanisms and
co-operating with HDAC1, which activates the DNMTs
and recruited by methyl CpG binding proteins [5]. On the
other hand, recent evidence demonstrates that human
ten-eleven translocation (TET) enzymes have catalytic
activity capable to convert 5-methylcytosine (5mC) to
5-hydroxymethylcytosine (5hmC), resulting in an initi-
ation of DNA demethylation [6].
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Currently, targeting enzymes that modify DNA methy-
lation is considered an attractive therapeutic strategy for
cancer treatment. Indeed, DNMT inhibition blocks the
methylation of newly synthesized DNA strands, resulting
in the reversion of the methylation status and the reacti-
vation of silenced genes, such as tumor suppressors [7].
Several DNMT inhibitors, including 5-aza-2′-deoxycyti-
dine (5-aza-dC), zebularine, and (−)-epigallocatechin-3-
gallate (EGCG), reduce DNA methylation and re-express
silenced genes. Thus, they have been suggested as poten-
tial anticancer drugs in various cancer cells in vitro and
in vivo, but side effects such as DNA mutagenesis and
cytotoxicity are still a cause for concern [7–9].
Hinokitiol (4-isopropyltropolone) is a component of
essential oils extracted from Chymacyparis obtusa
and has anti-infective, anti-oxidative effects, and anti-
tumor activities. The anti-tumor activity of hinokitiol
has been demonstrated in several types of cancer
cells by inhibiting cell growth and inducing apoptosis
[10–12]. However, the relevant molecular mecha-
nisms of hinokitiol regarding anti-cancer effects are
still unclear.
The goal of this study was to investigate a possible
mechanism of hinokitiol on DNA methylation in hu-
man colon cancer cell lines. Our data demonstrated
that hinokitiol decreased DNMT1 and UHRF1 expres-
sion and increased the level of TET1 in colon cancer
cell line HCT-116. Furthermore, hinokitiol altered the
methylation status of 10 hypermethylated genes in
colon cancer cells and significantly reactivated the
mRNA expression of O6-methylguanine DNA methyl-
transferase (MGMT), carbohydrate sulfotransferase 10
(CHST10), and B-cell translocation gene 4 (BTG4),
which are involved in cell proliferation or biological
oxidation [13–15].
Results
Hinokitiol inhibits colon cancer cell growth in a dose- and
time-dependent manner
To gain insight into the anti-proliferation effects of
hinokitiol in colon cancer cells, we treated HCT-116 and
SW480 cells with hinokitiol of different concentrations
and times. Using cell morphological observation, we
found that the number of cells decreased with increasing
concentrations of hinokitiol (Additional file 1A). To
compare the effects of hinokitiol on the viability of
colon cancer and normal colon cells, a MTT assay was
performed. As shown in Fig. 1, hinokitiol affected the
viability of HCT-116 and SW480 cells in dose- and
time-dependent manners. In contrast, the viability of
normal colon cells was maintained at concentrations
over 5 μM of hinokitiol. Our data showed that hinoki-
tiol had higher sensitivity in colon cancer cells than in
normal colon cells (P < 0.001).
Hinokitiol inhibits the expression of DNMT1 in HCT-116
cells
The expression patterns of DNMT1 in normal colon
cells and colon cancer cells were analyzed by RT-
PCR and qRT-PCR. In Fig. 2a and b, DNMT1
mRNA is highly expressed in colon cancer cells, es-
pecially in HCT-116 cells, while only slightly
expressed in CCD18Co cells. To gain insight into
the role of hinokitiol on DNA methylation, we mea-
sured DNMT1 expression after the hinokitiol treat-
ment. HCT-116 cells were exposed to the indicated
concentrations of hinokitiol for up to 72 hrs, and
their DNMT1 expression was analyzed every 24 h
using qRT-PCR. We found that hinokitiol reduced
Fig. 1 Hinokitiol inhibits the proliferation of colon cancer cells.
CCD18Co, HCT-116, and SW480 cells were treated with hinokitiol at
indicated concentrations for 72 h (a) and for periods (b). An equal
volume of DMSO was treated as a vehicle control. Cell proliferation
was measured through MTT assay. The results are representative of
three different experiments and expressed as the mean ± SD and
as percentage of control. ** indicates a significant difference at the
level of < 0.001. Normal colon cell line: CCD18Co; colon cancer cell
lines: HCT-116 and SW480
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DNMT1 mRNA expression in time- and dose-
dependent manners (P < 0.05) (Fig. 2c and d). In
addition, the effect of hinokitiol on the expression of
DNMT1 protein was confirmed using Western blot-
ting. As shown in Fig. 2e, hinokitiol (5 and 10 μM)
treatment decreased the protein level of DNMT1 in
a time-dependent manner. Furthermore, the expres-
sion levels of DNMT1 mRNA and protein with
10 μM of hinokitiol for 72 h were similar to that of
the 5-aza-dC treatment. We also showed the de-
creased expression of DNMT1 protein in SW480
cells treated with hinokitiol for 72 h (Additional file
1B). These results suggest that hinokitiol may be a
promising agent for DNMT1 inhibition in colon can-
cer cells.
Hinokitiol inhibits the expression of UHRF1 in HCT-116
cells
UHRF1 forms a complex with DNMT1 to maintain
DNA methylation. In order to investigate the involve-
ment of hinokitiol on UHRF1, the level of UHRF1
protein was measured in nuclear extracts of HCT-116
cells. Like in Fig. 2e, hinokitiol decreased level of
DNMT1 protein (Fig. 3a). In addition, the level of
UHRF1 protein was reduced in HCT-116 cells
exposed to 5 and 10 μM of hinokitiol, whereas the
control cells were not (Fig. 3b). Furthermore, knock-
down DNMT1 expression by siRNA reduced UHRF1
protein level (Fig. 3c). These results suggest that
hinokitiol may be associated with DNA demethylation
pathways in HCT-116 cells.
Fig. 2 Hinokitiol decreases DNMT1 mRNA and protein expression in HCT-116 cells. The level of DNMT1 mRNA was determined in HCT-116 and
SW480 cells using RT-PCR (a) and quantitative real-time PCR (qRT-PCR) (b). PCR products were gel-run in 2% agarose and visualized in ultraviolet
(UV). β-actin was used as a quantitative control. The quantitative DNMT1 mRNA level was measured using qRT-PCR after hinokitiol treatment at
indicated concentrations and times in HCT-116 cells (c and d). Total protein was isolated from cells treated with indicated concentrations of
hinokitiol for 72 h and western blotting was performed to detect DNMT1 expression (e). The results were representative of three independent
experiments. Cells treated with DMSO and 5-aza-dC were used as negative and positive controls, respectively. The β-actin was used as a loading
control. * indicates a significant difference at the level of < 0.05. M, 100 bp DNA ladder
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Hinokitiol enhances TET1 activity in HCT-116 cells
To confirm the effect of hinoikitiol on DNA demethyl-
ation, TET1 protein expression in nuclear fraction of
cells was evaluated by Western blotting. Hinokitiol in-
creased TET1 protein expression in a dose-dependent
manner and its level was higher than that of 5-aza-dC
treatment (Fig. 4a). In addition, the alteration of
5hmC level by hinokitiol treatment was assessed by
using ELISA in HCT-116 cells. Pretreatment with
10 μM hinokitiol increased the 5hmC level of total
DNA about 1.87-fold (from 0.040 to 0.075) compared
to the control (Fig. 4b). TET1 activity was also ana-
lyzed by measuring the levels of 5mC and 5hmC using
FACS analysis. Hinokitiol treatment induced a signifi-
cant enhancement of 5hmC level (fluorescence inten-
sity, FI:50) (P < 0.05). The 5mC level was not affected
in either treatment (Fig. 4c). These results indicate
that hinokitiol may cause DNA demethylation through
the downregulation of DNMT1 as well as the upregu-
lation of TET1 without reducing the level of 5mC in
colon cancer cells.
Hinokitiol restores the mRNA expression of MGMT, BTG4,
and CHST10 via demethylation
To verify the effect of demethylation and restoration of
hinokitiol on silenced genes resulting from DNA
Fig. 3 Hinokitiol decreases UHRF1 protein expression in HCT-116 cells. HCT-116 cells were treated with indicated concentrations of hinokitiol for 72 h.
Nuclear protein was extracted from the cells for western blot analysis with indicated antibodies (a-b). Lamin B was used for loading control. HCT-116 cells
were seeded into culture plates. After 24 h cultivation, cells were transiently transfected with siRNA DNMT1 and siRNA Control for 24, 48, 72 h, collected,
and total protein was extracted for western blot analysis using indicated antibodies (c). Experiments were done twice and representative blots were shown.
The expression level of each protein was quantified with the Image Studio Lite program, using Lamin B as a loading control. The histogram shows the
quantification expressed as ratio of the intensity of target gene/Lamin B. * indicates a significant difference at the level of < 0.05
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methylation, the levels of methylation and mRNA of
three CIMP markers and seven candidate genes in colon
cancer cells were analyzed by using QMSP and qRT-
PCR, respectively. In our previous study, we observed
that three CIMP markers (NEUROG1, TAC1, and
MGMT) and seven novel methylation candidate genes
(AKR1B1, CHST10, BTG4, ELOVL4, EYA4, SPG20, and
UNC5C) were hypermethylated with the loss of the
respective mRNA expression in HCT-116 cells but not
in CCD18Co cells [16]. Here, the methylation status of
these genes was reduced after treating the cells with
10 μM of hinokitiol for 72 h, though not completely
reduced, and hinokitiol-reversed methylation levels of
those genes were similar to that produced by a 5-aza-dC
(Fig. 5a). Moreover, hinokitiol significantly reactivated
the mRNA expression of MGMT, CHST10, and BTG4
(P < 0.05) (Fig. 5b).
Discussion
The key findings of this study are that there were signifi-
cant differences in sensitivity to hinokitiol between both
colon cancer cells and normal colon cells. This result
was similar to those of other reports showing that hino-
kitiol inhibits cell viability in colon cancer cells
Fig. 4 Hinokitiol increases TET1 expression via enhancement of 5hmC level in HCT-116 cells. HCT-116 cells were treated with 5 and 10 μM of hinokitiol
for 72 h and nuclear protein isolated from the cells was used to detect TET1 expression using western blot analysis (a). The expression level of each
protein was quantified with the Image Studio Lite program, using Lamin B as a loading control. The histogram shows the quantification expressed as
ratio of the intensity of target gene/Lamin B. Experiments were done twice and representative blots were shown. Contents of 5hmC measured from
cells treated with 10 μM of hinokitiol for 72 h using ELISA-based methylflash hydroxymethylated DNA quantification kit (b). The levels of 5mC and
5hmC were confirmed using flow cytometry analysis (c). All data are representative of three independent experiments performed in duplicate. The
results were representative of three independent experiments. Data are the means ± SE of results from at least three independent experiments. *
indicates a significant difference at the level of < 0.05
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(HCT116 and SW620) but not in normal colon cells
(CCD112CoN) [12]. Importantly, we demonstrated
that hinokitiol decreased the protein expression of
DNMT1 as well as UHRF1 in HCT-116 cells, and its
effect was similar with that of 5-aza-dC. Hinokitiol is
a natural tropolone-based monoterpenoid which is
found in cupressacceous plants. It has been shown
that hinokitiol possesses potent anti-tumor effects in
various cancer cell lines, including colon cancer, lung
adenocarcinoma, breast cancer, and melanoma cells,
by inducing cell cycle arrest or apoptosis [12, 17, 18].
However, previous studies have focused on elucidating
the molecular mechanism of hinokitiol-induced
anticancer effects through apoptosis pathways, and
the mechanisms underlying its effects are not yet fully
understood. In the present study, our results demon-
strated that hinokitiol has potential as a novel DNMT
inhibitor and could be associated with DNA methyla-
tion and thus provide hinokitiol as new therapeutic
candidate of colon cancer.
Epigenetic alterations, including DNA methylation and
histone modifications, play crucial roles in carcinogen-
esis and show possible targets for cancer treatment and
prevention. DNMT1 is most abundantly found in mam-
malian cells. Increased DNMT expression has been pro-
posed as a mechanism for the increased methylation
Fig. 5 Hinokitiol reduces methylation status and restores mRNA expression of MGMT, CHST10, and BTG4 genes. The effects of hinokitiol on the methylation
status of hypermethylated genes in HCT-116 cells compared with CCD18Co, were assessed using QMSP. The ratio of methylation intensity was determined
by the percentage of methylated reference (PMR). Cells treated with DMSO or 5-aza-dC at the same condition were used as negative and positive controls,
respectively (a) The mRNA expressions of MGMT, AKR1B1, CHST10, BTG4, and SPG20 genes were measured using qRT-PCR (b). Genomic DNA and total RNA
were extracted from cells treated with 10 μM of hinokitiol for 72 h. Data are the means ± SE of results from at least three independent experiments. *
indicates a significant difference at the level of < 0.05
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that occurs in the promoter region of tumors. In DNA
methylation, the role of DNMTs is more complex and
may involve changes in the expression of mRNA or pro-
tein. Previous studies have reported that DNMT1 inhib-
ition correlates with reduction in tumorigenicity and
increased expression of tumor suppressor genes, such as
p16 INK4a or p14 ARF [19, 20]. Thus, DNMT1 represents
one of the most attractive targets for development of
anticancer drugs. For example, azacytidine and decita-
bine are well known as DNMT inhibitors and the most
successful epigenetic modulators. Zebularine is another
DNMT inhibitor with concomitant inhibitory activity
towards cytidine deaminase. EGCG has dual actions
involving both DNA demethylation and posttranslational
histone modifications in cancer cells [7, 9, 21, 22]. How-
ever, there are still restrictions because of their toxicity
and poor stability or lack of information linked to the
possible clinical applications.
In the present study, we determined that hinokitiol
decreased UHRF1 proteins, which was similar or lower
with those of 5-aza-dC in HCT-116 cells and demon-
strated that such UHRF1 inhibition was caused by
DNMT1 reduced via transient transfection of siRNA
DNMT1. It has been reported that increased UHRF1 is
associated with cellular proliferation and has observed in
various types of cancers such as colorectal cancer. In
addition, UHRF1 binds to methylated promoters of
many tumor suppressor genes by forming complexes
with DNMTs and HDAC1, resulting ultimately in the
formation of cancer [23, 24]. Therefore, our results indi-
cate that hinokitiol may directly regulate the expression
of DNA methylation-related genes and may inhibit cellu-
lar proliferation in colon cancer. We also measured the
expression of HDAC1 protein to investigate whether
hinokitiol could affect histone deacetylation. Incubation
of cells to hinokitiol for 72 h resulted in a dose-
dependent decrease of HDAC1 protein levels in the
same cells, and its expression was lower than that of
5-aza-dC (Additional file 2).
Ten-eleven translocation (TET) enzymes are have
been identified as key players in demethylation of
cytosine. TET family genes are frequently observed in
human cancers [25]. Our data demonstrated that
hinokitiol increased the expression of TET1 protein
well known as DNA demethylation initiator in HCT-
116 and SW480 cells (Additional file 3) but did not
affect to the 5mC level. TET1 is an iron-dependent
α-ketoglutarate dioxygenase enzyme, and both fully
methylated and hemimethylated DNA in a CG or
non-CG context can serve as substrates for it. TET1
is responsible for converting 5mC to 5hmC methylcy-
tosine because of causing demethylation. Inactivation
of TET1 is associated with aberrant DNA methylation
in cancers. TET1 methylation is connected with CpG
island methylator phenotype (CIMP) in colorectal
cancer [26, 27]. On the other hand, several studies
reported that various chemical agents such as GSH,
vitamin B1, and vitamin E, appeared not to affect
5mC oxidation patterns despite DNA demethylation
effects via an increase of 5hmC level in cultured cells
[28, 29]. We also observed whether hinokitiol affects
both TET2 and TET3 protein levels. Our data showed
that hinokitiol had little effect on the expression of
TET3 protein in HCT-116 and SW480 cells
(Additional file 4). On the other hand, TET2 protein
expression did not detected in both cells (data not
shown). It might be because TET2 has a higher
expression level in hematological cells than TET1 or
TET3 and is recruited to genomic DNA by distinct
CXXC domain-independent mechanism unlike TET1
and TET3 [30]. Therefore, our results suggest that
hinokitiol may cause TET1-mediated DNA modifica-
tions in colon cancer cells without 5mC reduction.
Furthermore, our data demonstrates that hinokitiol
alters the methylation status of hypermethylated
genes in HCT-116 cells. Three CIMP markers and
seven new methylation candidates, which were re-
ported in our previous study [16], were selected ran-
domly and assessed by using QMSP for this study.
In this experiment, hinokitiol reduced methylation
status of ten genes and induced the significant res-
toration of MGMT, CHST10, and BTG4 mRNA
expression. MGMT is a DNA repair enzyme involved
in direct repair of alkylation damage products.
CHST10 is also known to inhibit the invasiveness of
melanoma cells, and BTG4 has anti-proliferative
properties [13, 15, 31]. The evidence for promoter
methylation patterns of those genes has been shown
in various cancers, including colon cancer [31–33].
Further studies are required to clarify these
relationships, particularly that hinokitiol induces ef-
fectively the reactivation of epigenetic-silencing
genes in colon cancer cells through combination
treatment with HDAC inhibitors or chemotherapeu-
tic drugs, including 5-FU and oxaliplatin.
Conclusions
This study has demonstrated the relationship be-
tween hinokitiol and DNA methylation in colon can-
cer cells and provided evidence for the potential of
hinokitiol as a novel DNMT1 inhibitor for colon
cancer treatment.
Methods
Cell culture and chemical treatment
The human colon cancer cell lines (HCT-116 and
SW480) and a normal colon cell line (CCD18Co)
were purchased from Korean Cell Line Bank (KCLB,
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Seoul, Korea) and the American Type Culture Collec-
tion (ATCC, Manassas, VA, USA). CRC cell lines
were maintained in RPMI-1640 medium (WELGENE,
Daejeon, Korea), and CCD18Co cell line was main-
tained in Eagle’s minimum essential medium (MEM,
WELGENE) containing 10% FBS and 1% penicillin-
streptomycin in a 5% CO2 atmosphere at 37 °C.
Hinokitiol (β-thujaplicin) and 5-aza-dC were dissolved
in dimethyl sulfoxide (DMSO). All chemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
As a control, 10 μM of 5-aza-dC was added freshly
every 24 h for 3 days.
Cell viability assay and morphologic
Cell viability was evaluated using MTT (3-(4, 5-Dimeth-
ylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay.
Briefly, cells were cultured in 96-well plates for 24 h and
then incubated with different concentrations of hinokitiol
(5–100 μM) for 72 h in a 5% CO2 incubator at 37 °C. At
the indicated times, 0.5 mg/ml MTT solution was
added to the wells. After a further 3 h of incubation,
the supernatant was discarded, and DMSO was added
to the plates. The color intensity was measured at
570 nm using microplate reader (SpectraMax Puls 384,
Molecular Devices, USA). The cell viability of each
sample was presented as a percentage of the viability of
culture treated with control. Cells treated with DMSO
were used as a control, which was considered to be
100% viable. These tests were performed on all samples
at least three times in the same assay. Changes in the
morphology of cells cultured with hinokitiol were ob-
served by using the EVOS® Image Systems (Thermo
Fisher Scientific, Hudson, NH, USA).
RNA extraction and reverse transcription (RT)-PCR
RNA was isolated from cells using the QIAzol lysis
reagent (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. cDNA synthesis was
performed in mixtures containing 2 μg of RNA, oli-
go-dT, and AMV-reverse transcriptase (Promega, Madi-
son, WI), following the manufacturer’s instructions.
PCR was performed using a SureCycler 8800 Thermal
Cycler (Agilent Technologies, Santa Clara, CA, USA).
The primers used in the PCR reactions are summarized
in Table 1. The PCR program was initiated at 95 °C for
10 min, followed by 35 cycles of 95 °C for 15 s, 60 °C
for 20 s, and 72 °C for 45 s. The amplified products
were separated on a 2% agarose gel, stained with Safe
Shine Green (Biosesang, Korea), and visualized using
BioDoc-It Imaging Systems (An Analytik Jena
Company, CA, USA). β-Actin was used to normalize
the amount of cDNA.
Quantitative real-time PCR (qRT-PCR)
To detect the mRNA level of DNMT1 and 10 hyper-
methylated genes in HCT-116 cells, qRT-PCR was per-
formed using ABI 7500 Real-Time PCR system (Applied
Biosystems, Foster City, CA, USA). The sets of primers
indicated (Table 1) and primer sequences were designed
using Primer3 ver. 0.4.0 (http://primer3.ut.ee/). The ex-
periments were repeated at least three times, and
each sample was analyzed in duplicate. The relative
amount of target genes was normalized by the
amount of β-actin used as the internal control in the
same sample and described as the ratio of each target
gene/β-actin. The cDNA of a known concentration
was prepared by serial dilutions, which were used as
the standard curve for quantification.
Genomic DNA extraction
Genomic DNA was extracted using the Wizard genomic
DNA purification kit (Promega), according to the manu-
facturer’s recommendations. The cells were lysed in
600 μl of nuclei lysis solution, RNase solution was
added, and the mixture was incubated at 37 °C for
30 min. The samples were mixed with 200 μl of protein
precipitation solution and centrifuged at 13,200 g for
5 min at room temperature. The supernatants were
transferred to fresh tubes, and the genomic DNA was
precipitated with isopropanol and washed with 70%
ethanol. The DNA eluted in 800 μl of DNA rehydration
solution was quantified using a NanoDrop ND-1000
spectrophotometer (Thermo Fisher Scientific).
Table 1 Primers for mRNA expression




DNMT1 F:AGACTACGCGAGATTCGAGTC 60 171
R:TTGGTGGCTGAGTAGTAGAGG
MGMT F:ACCGTTTGCGACTTGGTACT’ 54 268
R:CGGGGAACTCTTCGATAGCC
AKR1B1 F:CCCATGTGTACCAGAATGAGAA’ 58 362
R:CTGGAGATGGTTGAAGTTGGAG’
CHST10 F:GTGTGATTGGACACCACGAG’ 58 176
R:ATACAGGCGTCGGATGTCTC’
BTG4 F:GCAAGGAACCTCGTGTCATT 58 159
R:GCGAGCCATGGTAAGTGTTT’
SPG20 F:CCAACTGGAACAGAGCAGAAG’ 58 160
R:TTAGCCCTTTTTCCACGTTTT’
β-actin F:AGAGCTACGAGCTGCCTGAC 60 184
R:AGCACTGTGTTGGCGTACAG
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Western blot analysis
To extract total protein, cells were lysed in RIPA buf-
fer containing protease inhibitors (15 mM PMSF,
1 mM NaF, and 1 mM Na3VO4) and stored at −80 °C
until use. In addition, a nuclear protein was isolated
from cells using the EpiQuik nuclear extraction kit
(Epigentek Group Inc), according to the manufac-
turer’s instructions. The supernatants were collected
as total protein and nuclear protein extracts, respect-
ively. Aliquots of the supernatants (50 μg of total pro-
tein or nuclear extracts) were subjected to sodium
dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). The proteins were separated and then
transferred onto a nitrocellulose membrane (GE
Healthcare Life Science, Pittsburgh, PA, USA). The
membranes were incubated with anti-DNMT1 (sc-
20701), UHRF1 (Abcam, Cambridge, MA, USA),
TET1, TET2, TET3, Lamin B (Santa Cruz Biotechnol-
ogy, CA, USA), and β-actin (Sigma-Aldrich) anti-
bodies. After washing, the membranes were incubated
with horseradish peroxidase-conjugated secondary
antibodies (Santa Cruz Biotechnology). The bound
antibodies were visualized using the SuperSignal West
Dura Extended Duration Substrate (Thermo-Fisher
Scientific). β-actin for total protein and Lamin B for a
nuclear protein were used to confirm comparable
loading. The expression level of each protein was
quantified with the Image J program using Lamin B or
β-actin as a loading control.
Transient transfection of DNMT1 small RNA interference
(siRNA)
Cells were seeded at 0.3×105 cells/well in 6-well
plates and allowed to reach approximately 60% con-
fluence on the day of transfection. The siRNA con-
structs synthesized were: a mismatched siRNA control
and an siRNA against DNMT1 (Cosmogenetech,
Seoul, Korea). Cells were transfected with 50–100 nM
siRNA using lipofectamine 3000 based on the manu-
facturer’s protocol. Cells were harvested and examined
by qRT-PCR and western blot analysis at 24, 48, and
72 h after transfection.
Quantification of 5mC and 5hmC
For quantification of 5hmC, the ELISA-based methyl-
flash hydroxymethylated DNA quantification kit
(Epigentek Group Inc., NY, USA) was used. The initial
incubation time was 90 min, and the final developing
time was 10 min. The absolute quantification of stand-
ard curves was generated by plotting the concentration
of the positive control supplied with the assay against
the optical density at 450 nm after performing the
assay. The amount of 5hmC was assessed by absolute
quantification. For detection of the levels of 5mC and
5hmC by flow cytometry, cells were washed with PBS
supplemented with 0.1% Tween-20 and 1% bovine
serum albumin (PBST-BSA) and fixed with 0.25% para-
formaldehyde at 37 °C for 10 min and 88% methanol at
−20 °C for 1 h. Cells were permeated with 10% Triton-
X 100 at room temperature for 10 min and then treated
with 2 N HCL at 37 °C for 30 min and neutralized with
0.1 M sodium borate (pH 8.5). The cells were blocked
with 10% FBS in PBST-BSA at 37 °C for 20 min, incu-
bated with anti-5mC and anti-5hmC (Active Motif,
Carlsbad, CA, USA) antibodies at 37 °C for 50 min,
followed by staining with Cy3- or Alexa 488-conjugated
secondary antibodies (Jackson ImmunoResearch
Laboratories, PA, USA). The cells were washed with
PBS twice and analyzed by using a flow cytometer
(FACS Canto II, BD-Science, San Jose, CA, USA).
Bisulfite treatment and quantitative real-time
methylation-specific PCR (QMSP)
Bisulfite modification of DNA was performed using
the EpiTect Fast Bisulfite Conversion kits (Qiagen),
following the manufacturer’s directions. The reaction
was prepared by mixing 85 μl of bisulfite solution and
35 μl of DNA protect buffer in PCR tubes at room
temperature. The modified DNA was purified using
Qiaquick gel extraction kit (Qiagen) and eluted with
water. The methylation status of NEUROG1, TAC1,
MGMT, AKR1B1, CHST10, BTG4, ELOVL4, EYA4,
SPG20, and UNC5C genes was determined by QMSP
using ABI 7500 Real-time PCR Systems (Applied Bio-
systems). Primers for QMSP were designed for poten-
tial CpG islands near the translation start site using
the NCBI database and summarized in Table 2.
Methylation primers were designed using MethPrimer
software (http://www.urogene.org/methprimer/). The
PCR program was initiated at 95 °C for 5 min,
followed by 40 cycles of 95 °C for 15 s and 54–60 °C
for 1 min. The experiments were repeated at least
three times, and each sample was analyzed in dupli-
cates. Relative quantification of the amplified gene
levels in bisulfite-converted genomic DNA sample was
performed by measuring the threshold cycle (CT)
values of target genes and β-actin. The relative
amount of target genes was normalized by the amount
of β-actin used as the internal control in the same
sample and described as the ratio of each target gene/
β-actin. The bisulfite-converted genomic DNA of a
known concentration was prepared by serial dilutions,
which were used as the standard curve for quantifica-
tion. The modified genomic DNA by CpG methyl-
transferase M. SssI (NEB, Ipswich, MA, USA) was
used as a positive control. DNA methylation according
to M.SssI was verified using the restriction enzyme
BstUI (NEB).
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Statistical analysis
Results are presented as means ± SE. For statistical ana-
lyses, Student’s t-test for independent samples was used.
A value of P < 0.01 or < 0.05 was considered to indicate
statistical significance. All analyses were performed using
SigmaPlot12.0.
Additional files
Additional file 1: Hinokitiol affects cell morphology and DNMT1 protein
expression in colon cancer cells. HCT-116 cells were treated with 10 μM of
hinokitiol and cultured for 72 h. Changes in cell morphology was observed
under the phase contrast microscope by using EVOS Image System (a).
SW480 cells were treated with 10 μM of hinokitiol for 72 h. Nuclear protein
was isolated from the cells and 50 μg of protein was separated on SDS-
PAGE. After then, western blot analysis was performed with anti-DNMT1
and anti-Lamin B antibodies. Lamin B was used for loading control (b). Cells
treated with DMSO or 5-aza-dC were used as negative and positive controls,
respectively. (JPG 289 kb)
Additional file 2: Hinokitiol decreases HDAC1 protein expression in
HCT-116 cells. HCT-116 cells were treated with indicated concentrations
of hinokitiol for 72 h. Nuclear protein was extracted from the cells for
western blot analysis with anti-HDAC1 and anti-Lamin B antibodies
(Upper panel). Lamin B was used for loading control. Experiments were
done twice and representative blots were shown. The expression level of
each protein was quantified with the Image Studio Lite program, using
Lamin B as a loading control. The histogram shows the quantification
expressed as ratio of the intensity of target gene/Lamin B (lower panel).
(JPG 170 kb)
Additional file 3: Hinokitiol enhances of 5hmC level in SW480 cells. SW480
cells were treated with 5 and 10 μM of hinokitiol for 72 h and nuclear protein
was isolated. Contents of 5hmC was measured using ELISA-based methylflash
hydroxymethylated DNA quantification kit (a). The levels of 5mC and 5hmC
were confirmed using flow cytometry analysis (b). All data are representative
of three independent experiments performed in duplicate. The results were
representative of three independent experiments. Data are the means ± SE of
results from at least three independent experiments. (JPG 246 kb)
Additional file 4: Hinokitiol has no affect TET3 protein expression in colon
cancer cells. Colon cancer cells (HCT-116 or SW480) were treated with 10 μM
of hinokitiol for 72 h. Nuclear protein was extracted from the cells and then
western blot analysis was performed with anti-TET3 and anti-Lamin B
antibodies. Lamin B was used for loading control. Experiments were done
twice and representative blots were shown. Cells treated with DMSO or 5-
aza-dC were used as negative and positive controls, respectively. (JPG 102 kb)
Abbreviations
5-aza-dC: 5-aza-2′-deoxycytidine; 5-hmC: 5-hydroxymethylcytosine; 5-mC: 5-
methylacytosine; AKR1B1: Aldo-keto reductase 1; BTG4: B-cell translocation
gene 4; CHST10: carbohydrate sulfotransferase 10; CpG: Cytosine-phosphate-
guanine; DMSO: Dimethyl sulfoxide; DNMT: DNA methyltransferease;
ELOVL4: Elongation of very long chain fatty acids protein 4; EYA4: Eyes
absent homolog 4; GSH: Glutathione; HDAC: Histone deacethylase;
MGMT: O6-methylguanine DNA methyltransferase; NEUROG1: Neurogenin-1;
SPG20: Spastic paraplegia 20; TAC1: Protachykinin-1; TETs: Ten-eleven
translocation proteins; UHRF1: Ubiquitin-like plant homeodomain and RING
finger domain 1; UNC5C: Unc-5 homolog C
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Table 2 Primers for quantitative methylation-specific PCR (QMSP)
Gene Primer sequences (5′→ 3′) Annealing temp. (°C) Product size (bp) Location Gene bank
NEUROG1 F:TATGTAAATATTCGGGCGTTGTAC 58 199 (−155 ~ +43) NC_000005.9
R:GATCTCCTAAATAATATCGCCGAC
TAC1 F:TTAGATTTGTAGACGGAAGTAGGTC 58 139 (−135 ~ +3) NC_000007.13
R:GTAATTAAAAATTTCCGAAACGAT
MGMT F:GTTTGTATTGGTTGAAGGGTTATTT 58 109 (−292 ~ −184) NC_000010.10
R:CTAAAACAATCTACACATCCTCACT
AKR1B1 F:CGGAAGAAGTATTTTCGTCGA 58 166 (−120 ~ +45) NC_000007.13
R:CAATACGATACGACCTTAACCG
CHST10 F:TTTTGTAGCGGTAGAAAGGGAGATTCG 58 198 (−125 ~ +72) NC_000002.11
R:GACTTTAAAAACCAAAACGCCGAC
BTG4 F:GTATAATACGCGTAGTTGGGTTAGC 58 171 (−422 ~ −252) NC_0000011.9
R:AAAAAAACGAAAAAAACCTAAACG
ELOVL4 F:GAGTTTAGGTGTTTCGTTTTCGTTC 58 114 (−158 ~ −42) NC_000006.11
R:CCTCCCTCCCTAATATTAAAACTCG
EYA4 F:GTTATTCGAGGTTAAATAAAAACGG 58 149 (−198 ~ −50) NC_000006.11
R: ACTTACGCAAAAAAATAAAACGAA
SPG20 F:GTCGAGTAGTCGACGTGGTC 58 168 (−246 ~ −78) NC_000013.10
R:AATAATACGTAAAAAAACGTCCGTC
UNC5C F:GTTTAGGTTTGGCGTATCGC 58 219 (−463 ~ −245) NC_000004.11
R:GCCAAAAAAACGTAAAAAACG
β-actin F:TGGTGATGGAGGAGGTTTAGTAAGT 58 132 (−1645 ~ −1513) NC_000007.13
R: AACCAATAAAACCTACTCCTCCCTTAA
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